ExelixisEXEL
EXEL
About: Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Employees: 1,147
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 14 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
155% more first-time investments, than exits
New positions opened: 112 | Existing positions closed: 44
28% more capital invested
Capital invested by funds: $6.48B [Q3] → $8.28B (+$1.79B) [Q4]
18% more call options, than puts
Call options by funds: $58.6M | Put options by funds: $49.7M
12% more funds holding
Funds holding: 446 [Q3] → 501 (+55) [Q4]
6% more repeat investments, than reductions
Existing positions increased: 171 | Existing positions reduced: 161
0% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 7 (+0) [Q4]
0.62% less ownership
Funds ownership: 87.6% [Q3] → 86.99% (-0.62%) [Q4]
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$29
21%
downside
Avg. target
$38
3%
upside
High target
$45
22%
upside
14 analyst ratings
8 positive
57%
6 neutral
43%
0 negative
0%
Barclays Peter Lawson 12% 1-year accuracy 3 / 25 met price target | 21%downside $29 | Equal-Weight Maintained | 13 Feb 2025 |
HC Wainwright & Co. Robert Burns 27% 1-year accuracy 44 / 166 met price target | 9%upside $40 | Buy Reiterated | 13 Feb 2025 |
Citigroup David Lebowitz 63% 1-year accuracy 15 / 24 met price target | 22%upside $45 | Buy Maintained | 12 Feb 2025 |
Guggenheim Michael Schmidt 30% 1-year accuracy 8 / 27 met price target | 14%upside $42 | Buy Reiterated | 12 Feb 2025 |
Stephens & Co. Sudan Loganathan 26% 1-year accuracy 6 / 23 met price target | 21%downside $29 | Equal-Weight Reiterated | 12 Feb 2025 |
Financial journalist opinion
Based on 27 articles about EXEL published over the past 30 days
Positive
The Motley Fool
13 hours ago
Why Exelixis Stock Trounced the Market on Thursday
Cancer drug specialist Exelixis (EXEL 5.02%) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to push its shares 5% higher on the day.
Positive
Benzinga
18 hours ago
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
On Friday, Exelixis, Inc. EXEL authorized repurchasing up to an additional $500 million of the company's common stock before December 31, 2025.
Neutral
Business Wire
1 day ago
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company's Board of Directors has authorized the repurchase of up to an additional $500 million of the company's common stock before December 31, 2025. Exelixis plans on completing the currently ongoing $500 million stock repurchase program (SRP), announced in August 2024, in the second quarter of 2025, and commence stock repurchases under the newly authorized SRP thereafter. The February 2025 SRP is the fou.
Positive
Zacks Investment Research
1 day ago
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Positive
Zacks Investment Research
3 days ago
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
Neutral
Zacks Investment Research
4 days ago
International Markets and Exelixis (EXEL): A Deep Dive for Investors
Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Neutral
Business Wire
6 days ago
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC). After more than five years of follow-up, the findings demonstrated that efficacy benefits with CABOMETYX in combination with Opdivo were sustained long term. These results, including subgro.
Positive
Zacks Investment Research
1 week ago
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Neutral
Business Wire
1 week ago
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 Virtual Oncology Leadership Summit on Wednesday, February 19 at 2:00 p.m. ET / 11:00 a.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at least 30 days. About Exelixis Exelixis is a globally am.
Positive
Zacks Investment Research
1 week ago
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.
Charts implemented using Lightweight Charts™